Cargando…
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 ((211)At), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce availability of the nuclide. Despite a relatively large num...
Autores principales: | Lindegren, Sture, Albertsson, Per, Bäck, Tom, Jensen, Holger, Palm, Stig, Aneheim, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465635/ https://www.ncbi.nlm.nih.gov/pubmed/32077749 http://dx.doi.org/10.1089/cbr.2019.3055 |
Ejemplares similares
-
Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials
por: Aneheim, Emma, et al.
Publicado: (2015) -
Astatine-211 based radionuclide therapy: Current clinical trial landscape
por: Albertsson, Per, et al.
Publicado: (2023) -
Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
por: Timperanza, Chiara, et al.
Publicado: (2023) -
Towards elucidating the radiochemistry of astatine – Behavior in chloroform
por: Aneheim, Emma, et al.
Publicado: (2019) -
Evaluation of therapeutic efficacy of (211)At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
por: Palm, Stig, et al.
Publicado: (2020)